Strumento inattivo

Azioni pSivida Corp. Nasdaq

Azioni

Durata

Periodo

Stile

PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle	09/08/16
PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve	14/07/16
PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe	02/05/16
PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs	28/09/15
PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015	14/09/15

Settore

	Variaz. 1 gen.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31%	103 Mrd
REGENERON PHARMACEUTICALS, INC.	+0,56%	95,28 Mrd
ARGENX SE	+1,69%	22,15 Mrd
BIONTECH SE	-17,37%	21,02 Mrd
GENMAB A/S	-9,30%	18,15 Mrd
WUXI APPTEC CO., LTD.	-41,01%	16,74 Mrd
BEIGENE, LTD.	-14,85%	16,05 Mrd
NEUROCRINE BIOSCIENCES, INC.	+3,21%	13,68 Mrd
SAREPTA THERAPEUTICS, INC.	+33,54%	12,17 Mrd